SYNO / Synovis Life Technologies Inc - SEC 보고서, 연례 보고, 기업 사업 설명서

시노비스 라이프 테크놀로지스(Synovis Life Technologies Inc)
US
이 기호는 더 이상 활성화되지 않습니다.

기본 통계
CIK 780127
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Synovis Life Technologies Inc
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
February 24, 2012 15-12G

- FORM 15

FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 0-13907 SYNOVIS LIFE TECHNOLOGIES, INC. (Exact name of registrant a

February 15, 2012 SC 13G

SYNO / Synovis Life Technologies Inc / WATER ISLAND CAPITAL LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SYNOVIS LIFE TECHNOLOGIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 87162G105 - (CUSIP Number) 12/31/2011 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

February 14, 2012 8-K

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 14, 2012 Synovis Life Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 0-13907 41-1526554 (State or Other Jurisdiction of Incorpor

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or file with the S

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or fi

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

As filed with the Securities and Exchange Commission on February 14, 2012 Registration No.

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or fi

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

As filed with the Securities and Exchange Commission on February 14, 2012 Registration No.

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

As filed with the Securities and Exchange Commission on February 14, 2012 Registration No.

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

As filed with the Securities and Exchange Commission on February 14, 2012 Registration No.

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or file with the S

February 14, 2012 EX-3.1

BY-LAWS SYNOVIS LIFE TECHNOLOGIES, INC., A Minnesota corporation (Adopted as of February 14, 2012) ARTICLE I

Exhibit 3.1 BY-LAWS OF SYNOVIS LIFE TECHNOLOGIES, INC., A Minnesota corporation (Adopted as of February 14, 2012) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Minnesota shall be set forth in the Articles of Incorporation or in the most recent amendment of the Articles of Incorporation or Statement of the Board of Directors filed with the

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

S-8 POS 1 d298174ds8pos.htm POST-EFFECTIVE AMENDMENT NO.1 As filed with the Securities and Exchange Commission on February 14, 2012 Registration No. 333-80259 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYNOVIS LIFE TECHNOLOGIES, INC. (Exact name of registrant as specified

February 14, 2012 S-8 POS

- POST-EFFECTIVE AMENDMENT NO.1

POST-EFFECTIVE AMENDMENT NO.1 As filed with the Securities and Exchange Commission on February 14, 2012 Registration No. 333-14093 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SYNOVIS LIFE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Minnesota 4

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or file with the S

February 14, 2012 EX-24.1

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brett A. Reynolds as the undersigned’s true and lawful attorney-in-fact and agent, with the powers of substitution and revocation, for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to execute and/or fi

February 8, 2012 SC 13G/A

SYNO / Synovis Life Technologies Inc / BlackRock Inc. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) SYNOVIS LIFE TECHNOLOGIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 87162G105 - (CUSIP Number) December 30, 2011 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

January 20, 2012 SC 13G/A

SYNO / Synovis Life Technologies Inc / WealthTrust Axiom LLC - WEALTHTRUST AXIOM LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Synovis Life Technologies Inc (Name of Issuer) Common Stock par value $.01 (Title of Class of Securities) 87162G105 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p

January 13, 2012 DEFM14A

- DEFINITIVE SPECIAL PROXY STATEMENT

DEFM14A 1 d270889ddefm14a.htm DEFINITIVE SPECIAL PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use

January 6, 2012 EX-10.13

- EXHIBIT 10.13

Exhibit 10.13 Summary of Fiscal 2012 Named Executive Officer Compensation Set forth below is a summary of fiscal 2012 compensation arrangements between Synovis Life Technologies, Inc. (the “Company”) and certain of its executive officers who are expected to constitute the Company’s “named executive officers” (defined in Regulation S-K Item 402(a)(3)) for fiscal 2012. All of the Company’s executive

January 6, 2012 10-K

Annual Report - SYNOVIS LIFE TECHNOLOGIES INC 10-K 10-31-2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended October 31, 2011 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 0-13907 SYNOVIS LIFE TECHNOLOGIES, I

January 6, 2012 EX-10.12

Compensation Rate Fiscal 2012 Monthly Board member retainer $ 2,000 Fee per Board meeting attended $ 1,500 (2) Fee per Audit Committee meeting attended $ 1,000 (1)(2) Fee per Compensation Committee meeting attended $ 1,000 (1)(2) Fee per Governance C

Exhibit 10.12 Non-Employee Directors' Cash Compensation In fiscal 2012, non-employee directors of Synovis Life Technologies, Inc. (the “Company”) will receive cash compensation as outlined in the table below: Compensation Rate Fiscal 2012 Monthly Board member retainer $ 2,000 Fee per Board meeting attended $ 1,500 (2) Fee per Audit Committee meeting attended $ 1,000 (1)(2) Fee per Compensation Com

January 6, 2012 EX-21.1

SYNOVIS LIFE TECHNOLOGIES, INC. LIST OF SUBSIDIARIES OF THE COMPANY FOR THE YEAR ENDED OCTOBER 31, 2011 Name of Subsidiary Jurisdiction/State of Incorporation (1) Synovis Micro Companies Alliance, Inc. Minnesota (2) Synovis Orthopedic & Woundcare, In

Exhibit 21.1 SYNOVIS LIFE TECHNOLOGIES, INC. LIST OF SUBSIDIARIES OF THE COMPANY FOR THE YEAR ENDED OCTOBER 31, 2011 Name of Subsidiary Jurisdiction/State of Incorporation (1) Synovis Micro Companies Alliance, Inc. Minnesota (2) Synovis Orthopedic & Woundcare, Inc. Minnesota (3) Synovis Interventional Solutions, Inc. Minnesota (4) Bio-Vascular B.V., Breda Netherlands (5) Synovis Caribe, Inc. Puert

How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista